Pharmaceutical

Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 

Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.

Feb 22, 2024 - 18:00
Harmony wins orphan drug tag for pitolisant to treat Prader-Willi syndrome 
Harmony is advancing pitolisant into a Phase III clinical trial that is expected to start in Q1 2024.
Read the original article

Tags:

Previous Article

Immunocore and BMS partner to investigate first-line treatment for melanoma

Next Article

Immune-Onc’s antibody therapy collects second FDA orphan designation

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Colorado could cap payments for Amgen’s Enbrel

Colorado could cap payments for Amgen’s Enbrel

Feb 23, 2024

STAT+: Mass General Brigham CEO opens up about the Dana-Farber Cancer Institute split

STAT+: Mass General Brigham CEO opens up about the Dana...

Sep 30, 2023

Texas Medical Board under pressure to define emergency exception to abortion ban

Texas Medical Board under pressure to define emergency ...

Feb 3, 2024